Ozempic: an indication for type 2 diabetes
Ozempic contains semaglutide and its EU-authorised indication is treating adults with insufficiently controlled type 2 diabetes. Some people lose weight during treatment, but that does not make Ozempic the specifically authorised weight-management product.
Wegovy and Mounjaro for weight management
Wegovy also contains semaglutide, but has a specific weight-management indication and comes as a pen and, for adults, tablets. Mounjaro contains tirzepatide and also has a weight-management indication for adults who meet clinical criteria. A choice should not rest on the best-known name or a superficial comparison of milligram strengths.
What the doctor will assess
The assessment covers BMI, conditions, medicines, history and goals. If you are seeking treatment for obesity or overweight with related health problems, the doctor can explain authorised options, possible side effects and follow-up. A consultation does not guarantee a prescription.
Beware direct-sale offers
These medicines require a prescription. Be cautious of websites promising to send them without assessment or outside an authorised pharmacy. Costa provides medical consultation; dispensing and medicine payment take place at a pharmacy.
Same conversation, different authorisations
Ozempic and Wegovy contain semaglutide, but brand, product information and authorised uses differ. Ozempic is authorised for type 2 diabetes; Wegovy is authorised for weight management when clinical criteria are met. Mounjaro contains tirzepatide and has both diabetes and weight-management indications in the EU. A medicine having a familiar ingredient does not make the products interchangeable.
| Medicine | Ingredient | EU use relevant here |
|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes |
| Wegovy | Semaglutide | Weight management under its criteria |
| Mounjaro | Tirzepatide | Type 2 diabetes and weight management under its criteria |
These are summaries; prescribing decisions depend on the full product information and the patient. Supply issues also matter: European regulators have warned that off-label demand can affect access for people using GLP-1 medicines for approved indications. If weight management is your goal, ask about a product specifically authorised for that indication rather than assuming a diabetes brand is the default.
A research figure with the right context
The EMA reports about 15% mean loss with Wegovy injection versus 2% with placebo in a 68-week study. This is a group average for that particular trial, not a target or guarantee for every patient.
Wegovy injection study: average change
If you have diabetes and also want to lose weight
Diabetes and weight management can overlap, but they are not the same prescribing question. Tell the clinician what diabetes treatments you already use and whether you have had low blood sugar, digestive symptoms or other problems. Do not replace, share or change a medicine because someone online described a different brand as “the same drug”. The doctor can assess the authorised options for each condition and coordinate treatment.
When reading an article, check whether a percentage comes from a diabetes study, a weight-management study, or a head-to-head trial. Populations, endpoints and doses can differ. This is why we show the source beside each graph and avoid turning a group average into an individual promise.
Common questions
Are Ozempic and Wegovy the same?
They share the active ingredient semaglutide, but are products with different indications and treatment plans.
Which medicine is best for me?
There is no universal answer. A doctor must assess the indication, history, other treatments and safety.
Does Mounjaro contain semaglutide?
No. Mounjaro contains tirzepatide.